RxDoctor Payments Data

Perry Anarado, MD

Cardiovascular Disease · Beachwood, OHNPI 1538345202

Payments from drug & device makers

$767in general payments, 2019–2025

Across 44 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$203
  • Pfizer$197
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$187
  • Amgen$41
  • Boston Scientific$34
  • E.r. Squibb & Sons, L.L.C.$29
  • plus $75 from 5 others

What the payments were for

  • Food & beverage$74597%
  • Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$111,350
Medicare patients
693
Services billed
1,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$371,086
EntrestoSacubitril/Valsartan72$104,481
Repatha SureclickEvolocumab53$53,339
XareltoRivaroxaban47$48,273
Praluent PenAlirocumab26$31,817
BrilintaTicagrelor26$27,818
FarxigaDapagliflozin Propanediol20$22,173
Atorvastatin Calcium301$3,102
Amiodarone Hcl39$2,875
Metoprolol Succinate176$2,651
Prazosin Hcl47$2,497
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$1,964
Flecainide Acetate30$1,911
Ezetimibe55$1,814
Losartan Potassium161$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$197$371,086291 claims
NovartisEntresto$203$104,48172 claims
AstraZenecaBrilinta, Farxiga$14$49,99146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →